SCYNEXIS (LTS:0L49) EV-to-Revenue : 0.08 (As of May. 29, 2024)

View and export this data going back to 2018. Start your Free Trial

What is SCYNEXIS EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, SCYNEXIS's enterprise value is $11.8 Mil. SCYNEXIS's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $140.4 Mil. Therefore, SCYNEXIS's EV-to-Revenue for today is 0.08.

The historical rank and industry rank for SCYNEXIS's EV-to-Revenue or its related term are showing as below:

LTS:0L49' s EV-to-Revenue Range Over the Past 10 Years
Min: -81.5 Med: 27.47 Max: 1356.88
Current: 0.08

During the past 12 years, the highest EV-to-Revenue of SCYNEXIS was 1356.88. The lowest was -81.50. And the median was 27.47.

LTS:0L49's EV-to-Revenue is ranked better than
98.04% of 1022 companies
in the Drug Manufacturers industry
Industry Median: 2.315 vs LTS:0L49: 0.08

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-29), SCYNEXIS's stock price is $2.20. SCYNEXIS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $2.82. Therefore, SCYNEXIS's PS Ratio for today is 0.78.

SCYNEXIS EV-to-Revenue Historical Data

The historical data trend for SCYNEXIS's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS EV-to-Revenue Chart

SCYNEXIS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

455.51

8.68

5.12

0.17

SCYNEXIS Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															17.05	0.29	0.08	0.17	-0.16

Competitive Comparison of SCYNEXIS's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SCYNEXIS's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's EV-to-Revenue falls into.

SCYNEXIS EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

SCYNEXIS's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	11.759	/	140.385
	=	0.08

SCYNEXIS's current Enterprise Value is $11.8 Mil.
SCYNEXIS's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $140.4 Mil.

SCYNEXIS (LTS:0L49) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

SCYNEXIS's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	2.20	/	2.819
	=	0.78

SCYNEXIS's share price for today is $2.20.
SCYNEXIS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.82.

SCYNEXIS EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

SCYNEXIS (LTS:0L49) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (LTS:0L49) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

SCYX:USA 135A:Germany

Address

1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548

Website

https://www.scynexis.com

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

SCYNEXIS (LTS:0L49) Headlines

No Headlines